Literature DB >> 11803074

Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance.

R G Pebody1, N J Gay, L M Hesketh, A Vyse, P Morgan-Capner, D W Brown, P Litton, E Miller.   

Abstract

Measles and mumps, but not rubella, outbreaks have been reported amongst populations highly vaccinated with a single dose of measles-mumps-rubella (MMR) vaccine. Repeated experience has shown that a two-dose regime of measles vaccine is required to eliminate measles. This paper reports the effect of the first and second MMR doses on specific antibody levels in a variety of populations.2-4 years after receiving a first dose of MMR vaccine at age 12-18 months, it was found that a large proportion of pre-school children had measles (19.5%) and mumps (23.4%) IgG antibody below the putative level of protection. Only a small proportion (4.6%) had rubella antibody below the putative protective level. A total of 41% had negative or equivocal levels to one or more antigens. The proportion measles antibody negative (but not rubella or mumps) was significantly higher in children vaccinated at 12 months of age than at 13-17 months. There was no evidence for correlation of seropositivity to each antigen, other than that produced by a small excess of children (1%) negative to all three antigens. After a second dose of MMR, the proportion negative to one or more antigens dropped to <4%. Examination of national serosurveillance data, found that following an MR vaccine campaign in cohorts that previously received MMR, both measles and rubella antibody levels were initially boosted but declined to pre-vaccination levels within 3 years. Our study supports the policy of administering a second dose of MMR vaccine to all children. However, continued monitoring of long-term population protection will be required and this study suggests that in highly vaccinated populations, total measles (and rubella) IgG antibody levels may not be an accurate reflection of protection. Further studies including qualitative measures, such as avidity, in different populations are merited and may contribute to the understanding of MMR population protection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11803074     DOI: 10.1016/s0264-410x(01)00435-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  26 in total

Review 1.  Mumps and the UK epidemic 2005.

Authors:  Ravindra K Gupta; Jennifer Best; Eithne MacMahon
Journal:  BMJ       Date:  2005-05-14

2.  Towards elimination: measles susceptibility in Australia and 17 European countries.

Authors:  Nick Andrews; Annedore Tischer; Annette Siedler; Richard G Pebody; Christopher Barbara; Suzanne Cotter; Arnis Duks; Nina Gacheva; Kriz Bohumir; Kari Johansen; Joel Mossong; Fernando de Ory; Katarina Prosenc; Margareta Sláciková; Heidi Theeten; Marios Zarvou; Adriana Pistol; Kalman Bartha; Dani Cohen; Jo Backhouse; Algirdas Griskevicius
Journal:  Bull World Health Organ       Date:  2008-03       Impact factor: 9.408

3.  Toll-like receptor 7 and 8 polymorphisms: associations with functional effects and cellular and antibody responses to measles virus and vaccine.

Authors:  Holly D Clifford; Stephanie T Yerkovich; Siew-Kim Khoo; Guicheng Zhang; John Upham; Peter N Le Souëf; Peter Richmond; Catherine M Hayden
Journal:  Immunogenetics       Date:  2011-09-23       Impact factor: 2.846

4.  Humoral responses to independent vaccinations are correlated in healthy boosted adults.

Authors:  Lori Garman; Amanda J Vineyard; Sherry R Crowe; John B Harley; Christina E Spooner; Limone C Collins; Michael R Nelson; Renata J M Engler; Judith A James
Journal:  Vaccine       Date:  2014-08-17       Impact factor: 3.641

5.  Seroprevalence of measles, mumps and rubella among young adults, after 20 years of universal 2-dose MMR vaccination in Israel.

Authors:  Hagai Levine; Salman Zarka; Omer E Ankol; Vladi Rozhavski; Nadav Davidovitch; Yair Aboudy; Ran D Balicer
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  Guidelines for the Prevention and Control of Mumps Outbreaks in Canada.

Authors: 
Journal:  Can Commun Dis Rep       Date:  2010-01-04

7.  A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Megan O'Byrne; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  Vaccine       Date:  2011-05-01       Impact factor: 3.641

8.  Susceptibility to measles, mumps, and rubella in 5-year-old children in Flanders, Belgium.

Authors:  E Leuridan; K Maertens; M Wautier; V Hutse; H Theeten
Journal:  Eur J Pediatr       Date:  2015-01-13       Impact factor: 3.183

9.  Comparison of rubella seroepidemiology in 17 countries: progress towards international disease control targets.

Authors:  Anthony Nardone; Annedore Tischer; Nick Andrews; Jo Backhouse; Heidi Theeten; Nina Gatcheva; Marios Zarvou; Bohumir Kriz; Richard G Pebody; Kalman Bartha; Darina O'Flanagan; Dani Cohen; Arnis Duks; Algirdas Griskevicius; Joel Mossong; Christopher Barbara; Adrianna Pistol; Margareta Slaciková; Katarina Prosenc; Kari Johansen; Elizabeth Miller
Journal:  Bull World Health Organ       Date:  2008-02       Impact factor: 9.408

10.  Gender effects on humoral immune responses to smallpox vaccine.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; V Shane Pankratz; Robert A Vierkant; Robert M Jacobson; Margaret A K Ryan; Gregory A Poland
Journal:  Vaccine       Date:  2009-02-05       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.